CN109843857B - Ppar激动剂化合物的结晶和盐形式 - Google Patents

Ppar激动剂化合物的结晶和盐形式 Download PDF

Info

Publication number
CN109843857B
CN109843857B CN201780062034.5A CN201780062034A CN109843857B CN 109843857 B CN109843857 B CN 109843857B CN 201780062034 A CN201780062034 A CN 201780062034A CN 109843857 B CN109843857 B CN 109843857B
Authority
CN
China
Prior art keywords
disease
compound
syndrome
compounds
muscular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780062034.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN109843857A (zh
Inventor
B·拉古
S·特扎斯卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitobridge Inc
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of CN109843857A publication Critical patent/CN109843857A/zh
Application granted granted Critical
Publication of CN109843857B publication Critical patent/CN109843857B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201780062034.5A 2016-10-05 2017-10-05 Ppar激动剂化合物的结晶和盐形式 Active CN109843857B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404474P 2016-10-05 2016-10-05
US62/404,474 2016-10-05
PCT/US2017/055403 WO2018067860A1 (en) 2016-10-05 2017-10-05 Crystalline and salt forms of ppar agonist compounds

Publications (2)

Publication Number Publication Date
CN109843857A CN109843857A (zh) 2019-06-04
CN109843857B true CN109843857B (zh) 2023-01-06

Family

ID=60153508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780062034.5A Active CN109843857B (zh) 2016-10-05 2017-10-05 Ppar激动剂化合物的结晶和盐形式

Country Status (30)

Country Link
US (3) US10927094B2 (https=)
EP (1) EP3523283B1 (https=)
JP (1) JP7017563B2 (https=)
KR (1) KR20190057129A (https=)
CN (1) CN109843857B (https=)
AU (1) AU2017340763B2 (https=)
CA (1) CA3036587A1 (https=)
CO (1) CO2019003162A2 (https=)
CY (1) CY1124655T1 (https=)
DK (1) DK3523283T3 (https=)
ES (1) ES2887008T3 (https=)
HR (1) HRP20211341T1 (https=)
HU (1) HUE055678T2 (https=)
IL (1) IL265730B (https=)
JO (1) JOP20190039B1 (https=)
LT (1) LT3523283T (https=)
MA (1) MA46460A (https=)
MX (1) MX385973B (https=)
MY (1) MY202008A (https=)
PH (1) PH12019500727A1 (https=)
PL (1) PL3523283T3 (https=)
PT (1) PT3523283T (https=)
RS (1) RS62245B1 (https=)
RU (1) RU2759724C2 (https=)
SG (1) SG11201901995TA (https=)
SI (1) SI3523283T1 (https=)
TW (1) TWI769182B (https=)
UA (1) UA124770C2 (https=)
WO (1) WO2018067860A1 (https=)
ZA (1) ZA201901744B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
KR102667386B1 (ko) * 2015-10-07 2024-05-21 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
PL3523283T3 (pl) 2016-10-05 2021-12-13 Mitobridge, Inc. Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
WO2020033344A1 (en) * 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7397491B2 (ja) * 2018-10-23 2023-12-13 国立研究開発法人科学技術振興機構 ＰＰＡＲδ活性化剤
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
WO2022256540A1 (en) 2021-06-02 2022-12-08 Astellas Pharma Inc. Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
WO2025207099A1 (en) * 2024-03-28 2025-10-02 Astellas Pharma Inc. Ppar-delta inhibitors for preventing post-operative atrial fibrillation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072557A (zh) * 2004-12-17 2007-11-14 塞诺菲-安万特德国有限公司 Ppar激动剂用于治疗充血性心力衰竭的用途
CN101141957A (zh) * 2005-02-03 2008-03-12 Irm责任有限公司 作为ppar调节剂的化合物和组合物
CN101296892A (zh) * 2005-09-07 2008-10-29 普莱希科公司 Ppar活性化合物
CN102300847A (zh) * 2008-12-23 2011-12-28 拜欧珐姆德有限责任公司 Ppar激动剂组合物及其使用方法
CN102727489A (zh) * 2012-07-18 2012-10-17 西南大学 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396850B2 (en) 2003-01-06 2008-07-08 Eli Lilly And Company Pyrazole derivative as PPAR modulator
DE102006023336A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
KR102667386B1 (ko) 2015-10-07 2024-05-21 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
BR112018069930B1 (pt) 2016-04-13 2024-02-20 Mitobridge, Inc Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica
BR112019005539A2 (pt) 2016-10-05 2019-06-18 Mitobridge, Inc. métodos de tratamento de lesão renal aguda
PL3523283T3 (pl) 2016-10-05 2021-12-13 Mitobridge, Inc. Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072557A (zh) * 2004-12-17 2007-11-14 塞诺菲-安万特德国有限公司 Ppar激动剂用于治疗充血性心力衰竭的用途
CN101141957A (zh) * 2005-02-03 2008-03-12 Irm责任有限公司 作为ppar调节剂的化合物和组合物
CN101296892A (zh) * 2005-09-07 2008-10-29 普莱希科公司 Ppar活性化合物
CN102300847A (zh) * 2008-12-23 2011-12-28 拜欧珐姆德有限责任公司 Ppar激动剂组合物及其使用方法
CN102727489A (zh) * 2012-07-18 2012-10-17 西南大学 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Also Published As

Publication number Publication date
PL3523283T3 (pl) 2021-12-13
JOP20190039B1 (ar) 2023-03-28
UA124770C2 (uk) 2021-11-17
SG11201901995TA (en) 2019-04-29
HRP20211341T1 (hr) 2021-11-26
CN109843857A (zh) 2019-06-04
AU2017340763A1 (en) 2019-03-28
US20230257360A1 (en) 2023-08-17
BR112019006030A2 (pt) 2019-06-18
TWI769182B (zh) 2022-07-01
DK3523283T3 (en) 2021-06-28
RU2019110736A3 (https=) 2021-02-05
SI3523283T1 (sl) 2021-11-30
JP7017563B2 (ja) 2022-02-08
PT3523283T (pt) 2021-09-10
ZA201901744B (en) 2021-10-27
IL265730A (en) 2019-05-30
EP3523283B1 (en) 2021-06-09
TW201827409A (zh) 2018-08-01
US20200181108A1 (en) 2020-06-11
WO2018067860A1 (en) 2018-04-12
JP2019529516A (ja) 2019-10-17
CA3036587A1 (en) 2018-04-12
US11912681B2 (en) 2024-02-27
JOP20190039A1 (ar) 2019-03-07
US11530192B2 (en) 2022-12-20
MA46460A (fr) 2021-03-17
MY202008A (en) 2024-03-28
MX2019003945A (es) 2019-09-18
CY1124655T1 (el) 2022-07-22
US10927094B2 (en) 2021-02-23
RU2759724C2 (ru) 2021-11-17
KR20190057129A (ko) 2019-05-27
CO2019003162A2 (es) 2019-05-21
PH12019500727A1 (en) 2019-07-29
AU2017340763B2 (en) 2021-10-07
RU2019110736A (ru) 2020-11-06
MX385973B (es) 2025-03-18
RS62245B1 (sr) 2021-09-30
LT3523283T (lt) 2021-07-12
US20210171494A1 (en) 2021-06-10
IL265730B (en) 2022-09-01
HUE055678T2 (hu) 2021-12-28
EP3523283A1 (en) 2019-08-14
ES2887008T3 (es) 2021-12-21

Similar Documents

Publication Publication Date Title
CN109843857B (zh) Ppar激动剂化合物的结晶和盐形式
CN113004205B (zh) Ppar激动剂、化合物、药物组合物及其使用方法
TWI592407B (zh) 飢餓素ｏ－醯基轉移酶抑制劑
CN107428723B (zh) 生长素释放肽o-酰基转移酶抑制剂
HK40006508B (en) Crystalline and salt forms of ppar agonist compounds
HK40006508A (en) Crystalline and salt forms of ppar agonist compounds
BR112019006030B1 (pt) Formas cristalinas e de sal de compostos agonistas de ppar e seus usos
EA039771B1 (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения
WO2005095364A1 (ja) フェノキシ酢酸誘導体及びそれを用いた医薬
HK40054571A (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK40054571B (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK40054101A (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK40054101B (zh) Ppar激动剂、化合物、药物组合物及其使用方法
CN1938287A (zh) 苯氧基乙酸衍生物和包含其的药物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40006508

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant